

REMARKS

Reconsideration of the above-identified application in view of the amendments above and the remarks following is respectfully requested.

Claims 96-99 and 103-115 are pending in this case. Claims 72-95 have been withdrawn under a restriction requirement for a non-elected invention. Claims 96-99, 107, 108, 110-113 and 115 has been rejected under 35 U.S.C. § 112. Claims 96, 97 and 115 have now been amended.

35 U.S.C. § 112, First paragraph Rejection

The Examiner has rejected Claims 96-99, 107, 108, 110-113 and 115 for not enabling killing of any type of malignant glioma cell. The Examiner noted that the claims were enabling for malignant glioma cells that expressed the EGFR receptor.

The Examiner's rejection is traversed.

Notwithstanding, Applicant has amended Claim 96 to limit the malignant glioma cells to ones expressing the EGFR receptor.

Support for this amendment may be found on Page 12, lines 20-23.

Claims 97 and 115 have been amended to correct for antecedent basis.

In view of the above amendments and remarks it is respectfully submitted that claims 96-99 and 107-108, 110-113 and 115 are now in condition for allowance. Prompt notice of allowance is respectfully and earnestly solicited.

Respectfully submitted,

/Jason H. Rosenblum/

Jason H. Rosenblum
Registration No. 56437
Telephone: 718.246.8482

Date: November 2, 2010

Enclosures:

- Petition for Extension (One Month)